Wall Street analysts predict that Ovid Therapeutics Inc (NASDAQ:OVID) will announce ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Ovid Therapeutics’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.55). Ovid Therapeutics reported earnings of ($0.38) per share during the same quarter last year, which indicates a negative year over year growth rate of 55.3%. The firm is scheduled to report its next earnings report on Thursday, November 8th.
On average, analysts expect that Ovid Therapeutics will report full-year earnings of ($2.26) per share for the current financial year, with EPS estimates ranging from ($2.36) to ($2.15). For the next financial year, analysts forecast that the firm will report earnings of ($2.54) per share, with EPS estimates ranging from ($2.79) to ($2.25). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Ovid Therapeutics.
Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.07.
Several equities analysts recently commented on OVID shares. Zacks Investment Research upgraded shares of Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a report on Tuesday, September 4th. ValuEngine downgraded shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 14th. Piper Jaffray Companies set a $20.00 price target on shares of Ovid Therapeutics and gave the company a “buy” rating in a report on Monday, August 6th. Finally, BidaskClub downgraded shares of Ovid Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 27th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $18.08.
Shares of NASDAQ:OVID opened at $5.68 on Friday. The stock has a market cap of $139.66 million, a P/E ratio of -1.70 and a beta of 1.29. Ovid Therapeutics has a 12 month low of $5.20 and a 12 month high of $12.44.
In other news, Director Douglas E. Williams purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were bought at an average cost of $6.49 per share, for a total transaction of $32,450.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 43.90% of the company’s stock.
A number of large investors have recently modified their holdings of OVID. Schwab Charles Investment Management Inc. grew its stake in Ovid Therapeutics by 67.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 34,295 shares of the company’s stock worth $243,000 after acquiring an additional 13,785 shares in the last quarter. Northern Trust Corp grew its stake in Ovid Therapeutics by 81.7% in the 1st quarter. Northern Trust Corp now owns 118,430 shares of the company’s stock worth $837,000 after acquiring an additional 53,264 shares in the last quarter. BlackRock Inc. grew its stake in Ovid Therapeutics by 27.8% in the 1st quarter. BlackRock Inc. now owns 1,358,459 shares of the company’s stock worth $9,606,000 after acquiring an additional 295,247 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Ovid Therapeutics by 482.8% in the 1st quarter. JPMorgan Chase & Co. now owns 33,006 shares of the company’s stock worth $233,000 after acquiring an additional 27,343 shares in the last quarter. Finally, DRW Securities LLC bought a new position in Ovid Therapeutics in the 1st quarter worth about $108,000. Institutional investors own 31.06% of the company’s stock.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.